OSLO, Norway, Feb. 22, 2024 /PRNewswire/ --Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the international multicenter Phase III clinical study of Cevira® (APL-1702), the non-surgical treatment in development for cervical... read full story